Key facts
- This page summarizes Treace John T.'s Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 24 Aug 2026, 17:00.
Treace John T. - 20 Aug 2026 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- TMCI
- Reported as of
- 20 Aug 2026
- Net transaction value
- +$246,654
- SEC form
- 4
- Accepted by SEC
- 24 Aug 2026, 17:00:07 UTC
- Prior SEC filing
- 12 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa Taylor as Attorney-in-fact for John Treace
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Treace John T. filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 24 Aug 2026.
Change
- Previous filing in this sequence was filed on 12 Jun 2026.
- Current net transaction value: +$246,654.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001856380
Primary reporting owner
Treace John T.
- Relationship
- Chief Executive Officer, Director, 10%+ Owner
- Address
- C/O TREACE MEDICAL CONCEPTS, INC., 100 PALMETTO PARK PLACE, PONTE VEDRA
- Signature
- /s/ Lisa Taylor as Attorney-in-fact for John Treace
- Signature date
- 24 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TMCI
transaction
Common Stock
Purchase
- Transaction value
- $177,176
- Shares
- +39,944
- Change %
- +0.54%
- Price
- $4.44
- Shares after
- 7,388,383
- Date
- 20 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F2
TMCI
transaction
Common Stock
Purchase
- Transaction value
- $21,748
- Shares
- +5,000
- Change %
- +0.07%
- Price
- $4.35
- Shares after
- 7,393,383
- Date
- 21 Aug 2026
- Ownership
- Direct
- Footnotes
- F2
TMCI
transaction
Common Stock
Purchase
- Transaction value
- $47,731
- Shares
- +11,000
- Change %
- +0.15%
- Price
- $4.34
- Shares after
- 7,404,383
- Date
- 24 Aug 2026
- Ownership
- Direct
- Footnotes
- F2, F3
TMCI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,605,000
- Date
- 20 Aug 2026
- Ownership
- By spouse
- Footnotes
- F4
TMCI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,471,250
- Date
- 20 Aug 2026
- Ownership
- By spouse as trustee of a trust
- Footnotes
- F4
TMCI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,839,063
- Date
- 20 Aug 2026
- Ownership
- As trustee of a trust
- Footnotes
- F5
TMCI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 408,816
- Date
- 20 Aug 2026
- Ownership
- As co-trustee of a trust
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3198 to $4.5048 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
Footnote F2
Includes 542,784 restricted stock units.
Footnote F3
The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3097 to $4.3489 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
Footnote F4
The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.
Footnote F5
The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.